Sam Chang, MD, MBA, who has served as chair of the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), provides an overview of updated non-metastatic MIBC treatment guidelines, including a comprehensive treatment algorithm. He also discusses directions of future research for the disease.
Read More
Seth Lerner, MD, defines what places a bladder cancer patient into the BCG unresponsive category and treatment options in these cases. He touches on valrubicin, summarizes data regarding off-trial options such as gemcitabine, docetaxel, and the gem/doce combination, and discusses clinical trials for CG0070, Ad-IFN, and atezolizumab.
Read More
Michael S. Cookson, MD, describes the components of a quality transurethral resection of bladder tumor (TURBT), enhanced detection technologies such as blue light cystoscopy and narrow band imaging (NBI), and the induction of these new technologies into the American Urological Association (AUA) and Society of Urologic Oncology (SUO) bladder cancer guidelines and common practice.
Read More
Peter Black, MD, FRCSC, discusses the benefits and limitations of the currently FDA approved urinary biomarkers for bladder cancer. He defines criteria for the ideal biomarker, which would reduce the need for other diagnostic tests, have a high sensitivity and specificity rate, and be cost-effective for patients, as well as the possibility of using biomarkers in place of cystoscopy.
Read More
Sam Chang, MD, MBA, delineates the benefits and shortcomings of both robotic and open cystectomy, specifically in terms of morbidity, compilation, and recurrence rates for patients, and the learning curve associated with each method for clinicians. He also discusses how the financial cost of robotic surgery factors into this comparison.
Read More